Rasagiline

• CAT Number: I001397
• CAS Number: 136236-51-6
• Molecular Formula: C12H13N
• Molecular Weight: 171.24
• Purity: ≥95%
• Synonyms: Azilect®
• Target: Monoamine Oxidase
• Solubility: 10mM in water
• Storage: -20°C
• IUPAC Name: (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
• InChI: InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
• InChIKey: RUOKEQAAGRXIBM-GFCCVEGCSA-N
• SMILES: C#CCN[C@@H]1CCC2=CC=CC=C12

Rasagiline（Cat No.:I001397）is a selective, irreversible monoamine oxidase-B (MAO-B) inhibitor used in the treatment of Parkinson’s disease. By inhibiting MAO-B, rasagiline increases dopamine levels in the brain, which helps to alleviate symptoms such as tremors, stiffness, and bradykinesia (slowness of movement). It is often used as an adjunct therapy to levodopa in patients with Parkinson’s disease or as monotherapy in early stages. Rasagiline has neuroprotective properties and may slow disease progression. It is generally well tolerated, but side effects may include headache, nausea, and dizziness. Long-term use is monitored for potential cardiovascular effects.

Reference

[1]. Weinreb, O., et al., Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol, 2010. 92(3): p. 330-44.

[2]. Leegwater-Kim, J. and E. Bortan, The role of rasagiline in the treatment of Parkinson/’s disease. Clin Interv Aging, 2010. 5: p. 149-56.

[3]. Chen, J.J., D.M. Swope, and K. Dashtipour, Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson/’s disease. Clin Ther, 2007. 29(9): p. 1825-49.